Zyversa TherapeuticsZVSA
13F holders, Q1 2025 (March 31)7holders −1
1new positions
2sold out
$0.63avg. 13F price*
At the end of Q1 2025, 7 institutions reported holding Zyversa Therapeutics Inc. (ZVSA) in their 13F filings, down 1 from Q4 2024. 1 opened new positions and 2 sold out. The largest holders were UBS Group AG ($18K), Geode Capital Management, LLC ($14K) and Virtu Financial LLC ($11K).
- Company
- Zyversa Therapeutics Inc.
- CUSIP
- 98987D300
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $14K |
| Exits | 2 | $51K |
All 13F filers, Q4 2024 → Q1 2025: 45,848 shares bought and 57,056 shares sold, net −11,208 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| UBS Group AG | 0.00% | Add +576.5% | 28,327 | $18K |
| Geode Capital Management, LLC | 0.00% | New | 21,706 | $14K |
| Virtu Financial LLC | 0.00% | Reduce -30.6% | 17,527 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -38.1% | 2,155 | $1K |
| Bank of America Corp. | 0.00% | Add +1.8% | 111 | $70 |
| SBI Securities Co., Ltd. | 0.00% | No change | 50 | $31 |
| Morgan Stanley | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is ZVSA's weight in each manager's 13F, not the share of Zyversa Therapeutics Inc. the manager owns.